Rituximab-related viral infections in lymphoma patients (Q36871718)

16 August 2017

0 references

1 reference

title

Rituximab-related viral infections in lymphoma patients (English)

1 reference

16 August 2017

6

Kadri Altundag

1 reference

16 August 2017

Sercan Aksoy

1

1 reference

16 August 2017

Hakan Harputluoglu

2

1 reference

16 August 2017

Saadettin Kilickap

3

1 reference

16 August 2017

Didem Sener Dede

4

1 reference

16 August 2017

Omer Dizdar

5

1 reference

16 August 2017

Ibrahim Barista

7

1 reference

16 August 2017

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

48

1 reference

16 August 2017

7

1 reference

16 August 2017

1307-1312

1 reference

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

16 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

First Isolation of West Nile virus from a patient with encephalitis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Severe cytomegalovirus enterocolitis after standard chemotherapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Monoclonal antibodies and cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post Rituximab and autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Diabetes insipidus due to herpes encephalitis in a patient with diffuse large cell lymphoma. A case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Infectious and immunosuppressive complications of purine analog therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Successful treatment with lamivudine for reactivated hepatitis B infection following chemotherapy for non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701411441

10.1080/10428190701411441

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference